# reload+after+2024-01-21 13:45:40.093660
address1§332 Encinitas Boulevard
address2§Suite 102
city§Encinitas
state§CA
zip§92024
country§United States
phone§858 224 9600
website§https://www.kiorapharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
fullTimeEmployees§12
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Brian M. Strem Ph.D.', 'age': 43, 'title': 'President, CEO & Director', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 464932, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Melissa  Tosca CPA', 'age': 43, 'title': 'Executive Vice President of Finance', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 282283, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eric J. Daniels M.B.A., M.D.', 'age': 50, 'title': 'Chief Development Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 371471, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stefan  Sperl Ph.D.', 'title': 'Executive Vice President of CMC & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.314
currency§USD
dateShortInterest§1702598400
forwardEps§-0.82
exchange§NCM
quoteType§EQUITY
shortName§Kiora Pharmaceuticals, Inc.
longName§Kiora Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1423837800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§0a06c299-968e-31d2-9678-be3e3334b429
gmtOffSetMilliseconds§-18000000
targetHighPrice§33.0
targetLowPrice§2.0
targetMeanPrice§12.33
targetMedianPrice§2.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§3.21
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
